{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:44:05Z","timestamp":1789559045306,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T00:00:00Z","timestamp":1389916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00259-013-2441-8","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T12:04:36Z","timestamp":1389873876000},"page":"408-415","source":"Crossref","is-referenced-by-count":45,"title":["PET\/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study"],"prefix":"10.1007","volume":"41","author":[{"given":"Christelle","family":"Tychyj-Pinel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fulham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Meignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,17]]},"reference":[{"key":"2441_CR1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42\u201351. doi: 10.1016\/S0140-6736(10)62175-7 .","journal-title":"Lancet"},{"key":"2441_CR2","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011;29:3194\u2013200. doi: 10.1200\/JCO.2011.35.0736 .","journal-title":"J Clin Oncol"},{"key":"2441_CR3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579\u201386. doi: 10.1200\/JCO.2006.09.2403 .","journal-title":"J Clin Oncol"},{"key":"2441_CR4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571\u20138. doi: 10.1200\/JCO.2006.08.2305 .","journal-title":"J Clin Oncol"},{"key":"2441_CR5","first-page":"1059","volume":"47","author":"LK Shankar","year":"2006","unstructured":"Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059\u201366.","journal-title":"J Nucl Med"},{"key":"2441_CR6","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009;50:1257\u201360. doi: 10.1080\/10428190903040048 .","journal-title":"Leuk Lymphoma"},{"key":"2441_CR7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","volume":"51","author":"M Meignan","year":"2010","unstructured":"Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8\u20139 April 2010. Leuk Lymphoma 2010;51:2171\u201380. doi: 10.3109\/10428194.2010.529208 .","journal-title":"Leuk Lymphoma"},{"key":"2441_CR8","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","volume":"37","author":"SF Barrington","year":"2010","unstructured":"Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824\u201333. doi: 10.1007\/s00259-010-1490-5 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2441_CR9","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504\u20138.","journal-title":"Blood"},{"key":"2441_CR10","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"2441_CR11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"2441_CR12","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","volume":"28","author":"E Bachy","year":"2010","unstructured":"Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival\u2013a study from the groupe d\u2019etude des lymphomes de l\u2019adulte. J Clin Oncol 2010;28:822\u20139.","journal-title":"J Clin Oncol"},{"key":"2441_CR13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.beha.2004.08.019","volume":"18","author":"R Buckstein","year":"2005","unstructured":"Buckstein R, Pennell N, Berinstein NL. What is remission in follicular lymphoma and what is its relevance? Best Pract Res Clin Haematol 2005;18:27\u201356.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2441_CR14","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428190701422059","volume":"48","author":"S Bishu","year":"2007","unstructured":"Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 2007;48:1548\u201355.","journal-title":"Leuk Lymphoma"},{"key":"2441_CR15","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","volume":"14","author":"SA Jacobs","year":"2008","unstructured":"Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:7088\u201394.","journal-title":"Clin Cancer Res"},{"key":"2441_CR16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","volume":"8","author":"A Janikova","year":"2008","unstructured":"Janikova A, Bolcak K, Pavlik T, Mayer J, Kral Z. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma 2008;8:287\u201393.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2441_CR17","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","volume":"37","author":"L Dortz Le","year":"2010","unstructured":"Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, et al. Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010;37:2307\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2441_CR18","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdq024","volume":"21","author":"E Lopci","year":"2010","unstructured":"Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, et al. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol 2010;21:1877\u201383.","journal-title":"Ann Oncol"},{"key":"2441_CR19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","volume":"7","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Alinari L, Fanti S, Tani M, Stefoni V, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007;7:291\u20135.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2441_CR20","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol 2012;30:4317\u201322. doi: 10.1200\/JCO.2012.43.0934 .","journal-title":"J Clin Oncol"},{"key":"2441_CR21","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.110.080556","volume":"51","author":"E Itti","year":"2010","unstructured":"Itti E, Juweid ME, Haioun C, Yeddes I, Hamza-Maaloul F, El Bez I, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med 2010;51:1857\u201362. doi: 10.2967\/jnumed.110.080556 .","journal-title":"J Nucl Med"},{"key":"2441_CR22","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","volume":"53","author":"M Meignan","year":"2012","unstructured":"Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26\u201327 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012;53:1876\u201381. doi: 10.3109\/10428194.2012.677535 .","journal-title":"Leuk Lymphoma"},{"key":"2441_CR23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.acra.2009.10.026","volume":"17","author":"X Gao","year":"2010","unstructured":"Gao X, Xue Z, Xing J, Lee DY, Gottschalk SM, Heslop HE, et al. Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET\/CT imaging. Acad Radiol 2010;17:479\u201388. doi: 10.1016\/j.acra.2009.10.026 .","journal-title":"Acad Radiol"},{"key":"2441_CR24","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","volume":"17","author":"S W\u00f6hrer","year":"2006","unstructured":"W\u00f6hrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780\u20134.","journal-title":"Ann Oncol"},{"key":"2441_CR25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLM.2003.n.013","volume":"4","author":"RH Blum","year":"2003","unstructured":"Blum RH, Seymour JF, Wirth A, MacManus M, Hicks RJ. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin\u2019s lymphoma. Clin Lymphoma 2003;4:43\u20139.","journal-title":"Clin Lymphoma"},{"key":"2441_CR26","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","volume":"101","author":"R Elstrom","year":"2003","unstructured":"Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875\u20136.","journal-title":"Blood"},{"key":"2441_CR27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1023\/A:1011169332265","volume":"12","author":"G Jerusalem","year":"2001","unstructured":"Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin\u2019s lymphoma (NHL). Ann Oncol 2001;12:825\u201330.","journal-title":"Ann Oncol"},{"key":"2441_CR28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","volume":"107","author":"M Karam","year":"2006","unstructured":"Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175\u201383.","journal-title":"Cancer"},{"key":"2441_CR29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/108497801753131372","volume":"16","author":"F Najjar","year":"2001","unstructured":"Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin\u2019s lymphomas (NHL). Cancer Biother Radiopharm 2001;16:297\u2013304.","journal-title":"Cancer Biother Radiopharm"},{"key":"2441_CR30","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"N Tsukamoto","year":"2007","unstructured":"Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110:652\u20139.","journal-title":"Cancer"},{"key":"2441_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51:25\u201330.","journal-title":"J Nucl Med"},{"key":"2441_CR32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","volume":"71","author":"A Wirth","year":"2008","unstructured":"Wirth A, Foo M, Seymour JF, Macmanus MP, Hicks RJ. Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2008;71:213\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-013-2441-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2441-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:05:28Z","timestamp":1558699528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-013-2441-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,17]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["2441"],"URL":"https:\/\/doi.org\/10.1007\/s00259-013-2441-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,17]]}}}